Premium
Phase II evaluation of bleomycin. A Southwest Oncology Group study
Author(s) -
Haas Charles D.,
Coltman Charles A.,
Gottlieb Jeffrey A.,
Haut Arthur,
Luce James K.,
Talley Robert W.,
Samal Bohumil,
Wilson Henry E.,
Hoogstraten Barth
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197607)38:1<8::aid-cncr2820380103>3.0.co;2-4
Subject(s) - medicine , bleomycin , toxicity , pulmonary toxicity , lung , gastroenterology , oncology , lung cancer , urology , chemotherapy
Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice‐weekly doses of 10 mg/m 2 was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and 3/8 renal adenocarcinomas. The i.m. route is less, likely to cause pulmonary toxicity or hypotension than the i.v. route. Advanced age and total doses exceeding 200 mg were Associated with a higher risk of lung toxicity. All responders had shown at least improvement upon receiving 200 mg; higher total doses should be used only in responding patients.